<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107872</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1321</org_study_id>
    <nct_id>NCT02107872</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose&#xD;
      study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and&#xD;
      pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>visit 1 to day 183 (EOS)</time_frame>
    <description>Safety of REGN1500 will be assessed by physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations from visit 1 to day 183 [EOS (end of study)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>visit 1 to day 183</time_frame>
    <description>Serum concentration, amount of REGN1500 in the circulation, over time (visit 1 to day 183)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive REGN1500 or placebo in dosing cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1500</intervention_name>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_label>dosing cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>dosing cohort 1</arm_group_label>
    <arm_group_label>dosing cohort 2</arm_group_label>
    <arm_group_label>dosing cohort 3</arm_group_label>
    <arm_group_label>dosing cohort 4</arm_group_label>
    <arm_group_label>dosing cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
          -  Otherwise healthy men and women ages 18 to 65 years, inclusive&#xD;
&#xD;
          -  Body mass index of 18.0 kg/m2to 38.0 kg/m2, inclusive&#xD;
&#xD;
          -  Normal standard 12-lead ECG&#xD;
&#xD;
          -  Willing to refrain from the consumption of alcohol for 24 hours prior to each study&#xD;
             visit&#xD;
&#xD;
          -  Willing to consistently maintain his/her usual diet for the duration of the study&#xD;
&#xD;
          -  Willing to refrain from strenuous exercise for the duration of the trial&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  For sexually active men and women of childbearing potential, willingness to utilize&#xD;
             adequate contraception and not become pregnant (or have their partner[s] become&#xD;
             pregnant) during the full duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant abnormalities observed during the screening visit&#xD;
&#xD;
          -  History of drug or alcohol abuse within 1 year of screening&#xD;
&#xD;
          -  Receipt of another investigational drug or therapy within 30 days or at least 5&#xD;
             half-lives (whichever is longer), of the investigational drug prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Significant concomitant illness or history of significant illness such as cardiac,&#xD;
             renal, neurological, endocrinological, metabolic or lymphatic disease, or any other&#xD;
             illness or condition that may adversely affect the subjects participation in this&#xD;
             study&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) antibody; and/or positive&#xD;
             hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at the&#xD;
             screening visit&#xD;
&#xD;
          -  Hospitalization for any reason within 60 days of screening&#xD;
&#xD;
          -  History or presence of malignancy within 5 years prior to the screening visit (other&#xD;
             than successfully treated non-metastatic cutaneous squamous cell or basal cell&#xD;
             carcinoma, and/or localized carcinoma in situ of the cervix&#xD;
&#xD;
          -  Any medical or psychiatric condition which, in the opinion of the investigator, would&#xD;
             place the subject at risk, interfere with participation in the study or interfere with&#xD;
             the interpretation of the study results&#xD;
&#xD;
          -  Any subject who is the investigator or any sub-investigator, research assistant,&#xD;
             pharmacist, study coordinator, or other staff directly involved in the conduct of the&#xD;
             protocol, or family member of staff involved in the conduct of the protocol&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
        Note: The information listed above is not intended to contain all considerations relevant&#xD;
        to a patient's potential participation in this clinical trial and not all inclusion/&#xD;
        exclusion criteria are listed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

